TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05897775

Intervention type: DEVICE
Group type: OTHER
Intervention: Deep brain stimulation
Description: Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week.
Study: NCT06445439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing rate of 80 bpm
Description: Pacing rate of 80 bpm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing rate of 80 bpm
Description: Pacing rate of 80 bpm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing rate of 60 bpm
Description: Pacing rate of 60 bpm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing rate of 60 bpm
Description: Pacing rate of 60 bpm
Study: NCT05681481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Prednisone
Study: NCT05280652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and culinary intervention
Description: Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and culinary intervention
Description: Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention
Description: Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
Study: NCT06639867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-based home physiotherapy
Description: VR-based home physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy care
Description: Standard physiotherapy care as prescribed by the treating physiotherapist
Study: NCT06639191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-AKIR001
Description: Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participants in the previous cohort have received at least one dose of the IMP without dose-limiting toxicities during a follow-up period of at least six weeks.~The \[177Lu\]Lu-AKIR001 protein mass dose and activity are predefined for each cohort, and could be adjusted according to the results of previous cohort(s) to ensure the safety of participants. The initial design of the trial encompasses five cohorts to escalate both \[177Lu\]Lu-AKIR001 pmd, from 50 mg to 100 mg, and activity, from 0.75 to 3.0 GBq.
Study: NCT06640907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized e-Perinatal mHealth intervention integrated in maternal routine care
Description: The mHealth app provides psychoeducational materials, video-guided physical activities, mood tracking features, personalized recommendations, and community features. Additionally, professionals involved in this group are specifically trained to incorporate the mHealth app into their routine care practices, enhancing their ability to support mental health during the perinatal period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual perinatal care with general prenatal and postnatal health information
Description: Usual prenatal and postnatal health care, including regular health check-ups. They also gain access to public health resources and perinatal information distributed via email.
Study: NCT06638853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance Skills Training
Description: These lessons are adapted from DBT Skills in Schools: Skills Training for Emotional Problem Solving for Adolescents (DBT STEPS-A) by Mazza et al. and include elements of mindfulness training, psychoeducation about emotions, and techniques/skills for managing extreme emotions.
Study: NCT06640179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Contacts
Description: Participants will receive brief conducts (\<10 minutes) remotely (telephone or video platform) with the research staff at weeks 6, 12, and 18.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Sessions
Description: Participants will be provided weekly individual behavioral sessions during the 6-month intervention to assist in supporting recommended changes in energy intake (diet) and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: An energy balanced diet to meet energy needs that will allow for weight maintenance will be prescribed. This will be estimated using the Mifflin-St. Joer equation to estimate resting metabolic rate and for most participants we anticipate using a physical activity correction of 1.3 to account for energy needs for physical activity. This will provide the initial estimate of energy intake needs to maintain weight stability; however, the prescribed level of energy intake will be adjusted at 4-week intervals across the intervention based on the observed changes in weight, eating behaviors, and physical activity patterns in an effort to prevent excessive weight gain. Within the context of this level of energy intake, we will prescribe a diet that is consistent with the dietary recommendations of the National Kidney Foundation.
Study: NCT05138107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synochi Scar Spray Cosmetic
Description: Application of the cosmetic on each skin graft in a blinded fashion in different sections for a 9 month duration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Synochi Scar Spray Placebo
Description: Application of the placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.
Study: NCT05081765

Intervention type: DRUG
Intervention: Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)
Description: correlation between C through and taken drug

Intervention type: DRUG
Intervention: Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)
Description: correlation between C through and taken drug

Intervention type: DRUG
Intervention: Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)
Description: correlation between C through and taken drug

Intervention type: DEVICE
Intervention: Lynparza
Description: correlation between C through and taken drug

Intervention type: DEVICE
Intervention: Lynparza
Description: correlation between C through and taken drug

Intervention type: DEVICE
Intervention: Lynparza
Description: correlation between C through and taken drug
Study: NCT06640179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress in 4-week intervals from an initial amount of 50 minutes per week to 150 minutes per week across the initial 6 months of the intervention. Moderate intensity will be prescribed, and will be anchored using RPE (rating of perceived exertion) to allow intensity to be self-regulated according to the participant's capacity. Physical activity will be prescribed in the form of walking; however, the participant will be permitted to engage in other forms of physical activity that meet the recommended dose and intensity.
Study: NCT06638008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perineural injection
Description: perineural intervention of placental growth factor in one group and PRP in other group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perineural injection
Description: perineural intervention of placental growth factor in one group and PRP in other group
Study: NCT06639282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siponimod
Description: Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
Study: NCT06639035

Intervention type: OTHER
Intervention: External oblique intercostal plane block
Description: The external oblique intercostal plane block is applied to the patients at the end of the surgery.

Intervention type: OTHER
Intervention: intavenous tramadol
Description: Intravenous tramadol will be administered with patient-controlled analgesia

Intervention type: OTHER
Intervention: intavenous tramadol
Description: Intravenous tramadol will be administered with patient-controlled analgesia
Study: NCT06642649

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia (control group)
Description: Only General Anestesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia + Spinal anesthesia combined
Description: General anesthesia + spinal anesthesia with local anesthetic and morfine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia + Spinal anesthesia combined
Description: General anesthesia + spinal anesthesia with local anesthetic, morfine and fentanyl
Study: NCT06641388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebronucimab
Description: Ebronucimab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebronucimab
Description: Ebronucimab subcutaneous injection
Study: NCT06643143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IkT-001Pro
Description: IkT-001Pro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IkT-001Pro
Description: IkT-001Pro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06643520

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19-gauge
Description: All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 19 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22-gauge
Description: All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely.~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 22 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations.
Study: NCT06644807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Cortex Stimulation
Description: Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Stimulation
Description: Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
Study: NCT06644105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefditoren pivoxil tablets
Description: took cefditoren pivoxil tablets 200mg after
Study: NCT05176665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB-01
Description: EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
Study: NCT04506892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: meditation
Study: NCT05883709

Intervention type: DRUG
Intervention: Tafasitamab Injection
Description: The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients

Intervention type: DRUG
Intervention: Tafasitamab Injection
Description: The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
Study: NCT04588883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kuja Pamoja - HIV
Description: Information has been provided in the treatment arm description.
Study: NCT06389032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentor Support and Caregiver Education
Description: 12- week modular curriculum with handbook (PDF and Website version), additional resources and weekly phone discussions with Lewy Body Dementia (LBD) peer mentor/mentee.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Mentor Support and Caregiver Education
Description: 12- week modular curriculum with handbook (PDF and Website version), additional resources and weekly phone discussions with Lewy Body Dementia (LBD) peer mentor/mentee.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Education
Description: 12-weeks of receiving weekly curated list of Lewy Body Dementia (LBD) educational resources based on the weekly topics via email.
Study: NCT06636578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: will receive 30 ml of 0.25% of plain ropivacaine for each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: will receive 30 ml of 0.25% of plain ropivacaine for each side.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: fentanyl
Description: will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
Study: NCT06628986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: 20 minutes once a week for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NLP
Description: NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control
Description: control group, no practice,
Study: NCT05989997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-SNA002
Description: 68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
Study: NCT05621837

Intervention type: OTHER
Intervention: MDSC quantification
Description: Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).

Intervention type: OTHER
Intervention: MDSC quantification
Description: Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).

Intervention type: OTHER
Intervention: MDSC quantification
Description: Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).

Intervention type: OTHER
Intervention: MDSC quantification
Description: Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).

Intervention type: OTHER
Intervention: MDSC quantification
Description: Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).

Intervention type: OTHER
Intervention: MDSC quantification
Description: Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
Study: NCT04931017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo bronchoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Undergo bronchoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Metformin Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Metformin Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06569316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood or saliva and leftover tissue sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive care plan recommendations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06569459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib Injection [Cosela]
Description: Chemoradiotherapy and immunotherapy with Trilaciclib in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
Study: NCT05054101

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Real-time assessment using the VieCovid2020 smartphone application
Description: a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time assessment using the VieCovid2020 smartphone application
Description: a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention